New Developments in CKD-MBD. The present state and problem of CKD-MBD treatment in Japan

Masatomo Taniguchi

Research output: Contribution to journalArticle

Abstract

When considering the CKD-MBD treatment of our country, we should take account of clinical background, such as a high ratio of long-term hemodialysis patients, a small number of renal transplantation surgeries, etc. Furthermore, insurance systems differ from country to country and the universal public insurance system will also have some influences on medical circumstances in Japan. Re-considering the CKD-MBD treatment of Japan from these perspectives, there remain some issues to be addressed ; a choice of which phosphate binder is the best, a selection of treatment for severe secondary hyperparathyroidism, cinacalcet or surgery. The issues about native vitamin D agent and the treatment for osteoporosis in CKD patients should be also resolved. This article argues the present situation of CKD-MBD treatment and considers new issues and problems for more sophisticated CKD-MBD therapy in Japan.

Original languageEnglish (US)
Pages (from-to)1839-1844
Number of pages6
JournalClinical calcium
Volume24
Issue number12
StatePublished - Dec 1 2014

Fingerprint

Chronic Kidney Disease-Mineral and Bone Disorder
Japan
Insurance
Therapeutics
Secondary Hyperparathyroidism
Vitamin D
Kidney Transplantation
Osteoporosis
Renal Dialysis
Phosphates

ASJC Scopus subject areas

  • Medicine(all)

Cite this

New Developments in CKD-MBD. The present state and problem of CKD-MBD treatment in Japan. / Taniguchi, Masatomo.

In: Clinical calcium, Vol. 24, No. 12, 01.12.2014, p. 1839-1844.

Research output: Contribution to journalArticle

@article{26cd0bf533a3475d803da3877fcc0e87,
title = "New Developments in CKD-MBD. The present state and problem of CKD-MBD treatment in Japan",
abstract = "When considering the CKD-MBD treatment of our country, we should take account of clinical background, such as a high ratio of long-term hemodialysis patients, a small number of renal transplantation surgeries, etc. Furthermore, insurance systems differ from country to country and the universal public insurance system will also have some influences on medical circumstances in Japan. Re-considering the CKD-MBD treatment of Japan from these perspectives, there remain some issues to be addressed ; a choice of which phosphate binder is the best, a selection of treatment for severe secondary hyperparathyroidism, cinacalcet or surgery. The issues about native vitamin D agent and the treatment for osteoporosis in CKD patients should be also resolved. This article argues the present situation of CKD-MBD treatment and considers new issues and problems for more sophisticated CKD-MBD therapy in Japan.",
author = "Masatomo Taniguchi",
year = "2014",
month = "12",
day = "1",
language = "English (US)",
volume = "24",
pages = "1839--1844",
journal = "Clinical calcium",
issn = "0917-5857",
publisher = "Iyaku (Medicine & Drug) Journal Co",
number = "12",

}

TY - JOUR

T1 - New Developments in CKD-MBD. The present state and problem of CKD-MBD treatment in Japan

AU - Taniguchi, Masatomo

PY - 2014/12/1

Y1 - 2014/12/1

N2 - When considering the CKD-MBD treatment of our country, we should take account of clinical background, such as a high ratio of long-term hemodialysis patients, a small number of renal transplantation surgeries, etc. Furthermore, insurance systems differ from country to country and the universal public insurance system will also have some influences on medical circumstances in Japan. Re-considering the CKD-MBD treatment of Japan from these perspectives, there remain some issues to be addressed ; a choice of which phosphate binder is the best, a selection of treatment for severe secondary hyperparathyroidism, cinacalcet or surgery. The issues about native vitamin D agent and the treatment for osteoporosis in CKD patients should be also resolved. This article argues the present situation of CKD-MBD treatment and considers new issues and problems for more sophisticated CKD-MBD therapy in Japan.

AB - When considering the CKD-MBD treatment of our country, we should take account of clinical background, such as a high ratio of long-term hemodialysis patients, a small number of renal transplantation surgeries, etc. Furthermore, insurance systems differ from country to country and the universal public insurance system will also have some influences on medical circumstances in Japan. Re-considering the CKD-MBD treatment of Japan from these perspectives, there remain some issues to be addressed ; a choice of which phosphate binder is the best, a selection of treatment for severe secondary hyperparathyroidism, cinacalcet or surgery. The issues about native vitamin D agent and the treatment for osteoporosis in CKD patients should be also resolved. This article argues the present situation of CKD-MBD treatment and considers new issues and problems for more sophisticated CKD-MBD therapy in Japan.

UR - http://www.scopus.com/inward/record.url?scp=85016468963&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85016468963&partnerID=8YFLogxK

M3 - Article

VL - 24

SP - 1839

EP - 1844

JO - Clinical calcium

JF - Clinical calcium

SN - 0917-5857

IS - 12

ER -